Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Shares Issued (2022 - 2025)

BioXcel Therapeutics (BTAI) has 4 years of Shares Issued data on record, last reported at $38.2 million in Q3 2025.

  • For Q3 2025, Shares Issued rose 8087.15% year-over-year to $38.2 million; the TTM value through Sep 2025 reached $59.4 million, up 10.51%, while the annual FY2024 figure was $39.7 million, 46.82% up from the prior year.
  • Shares Issued reached $38.2 million in Q3 2025 per BTAI's latest filing, up from $140000.0 in the prior quarter.
  • Across five years, Shares Issued topped out at $38.2 million in Q3 2025 and bottomed at $48000.0 in Q3 2022.
  • Average Shares Issued over 4 years is $10.3 million, with a median of $467000.0 recorded in 2024.
  • Peak YoY movement for Shares Issued: surged 52948.0% in 2023, then plummeted 73.61% in 2024.
  • A 4-year view of Shares Issued shows it stood at $50000.0 in 2022, then soared by 52948.0% to $26.5 million in 2023, then tumbled by 73.61% to $7.0 million in 2024, then surged by 446.12% to $38.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Issued were $38.2 million in Q3 2025, $140000.0 in Q2 2025, and $14.0 million in Q1 2025.